伏立康唑治疗92例肺部侵袭性真菌感染的疗效与评价

The efficacy of voriconazole therapy for invasive pulmonary fungal infection in 92 patients

目的 评价伏立康唑对呼吸科肺部侵袭性真菌感染患者的疗效与副作用.方法 选取我院呼吸科92例侵袭性真菌感染患者,均给予伏立康唑,观察症状体征、实验室及细菌学指标,并对该药疗效与副作用进行描述与评价.结果 可评价疗效的患者中,临床痊愈率为58.33%,总有效率为80.56%.真菌学疗效清除率为76.67%.不良反应主要为精神神经症状,包括幻觉49例（53.26%）,视觉异常26例（28.26%）,失眠22例（23.91%）,其中2例患者停用伏立康唑或换用其他抗真菌药,其余均在足疗程停药后,自动恢复.因原发病病情加重死亡18例.结论 伏立康唑是一种新型的抗真菌药物,作为治疗侵袭性肺部真菌感染治疗的一线药物,具有高效安全的特点.

Objective To explore the efficacy and side effects of voriconazole therapy of invasive pulmonary fungal infection.Methods 92 patients received therapy with voriconazole.The symptoms and signs,laboratory test results,and bacteriological indexes were determined.The efficacy and side effects of voriconazole were assessed.Results The curative rate was 58.33% and total effective rate was 80.56%.Mycological clearance rate was 76.67%.Adverse reactions were mainly mental and psychic,including 49 （53.26%） cases of hallucination,26 （28.26%） visual disturbance,and 22 （23.91%） insomnia.2 patients had to discontinue voriconazole because of its severe reactions.The adverse reactions disappeared automatically in other patients after the completion of treatment.18 pateints died of worsening of the primary disorders.Conclusions Voriconazole is a novel antifungal agent.As a first-line medication for invasive pulmonary fungal infection,it is effective and safe.